Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease

Parkinsonism and Related Disorders

Volumn 50, Issue , 2018, Pages 108-112

  Goldstein, David S ^a   Holmes, Courtney ^a   Lopez, Grisel J ^b   Wu, Tianxia ^a   Sharabi, Yehonatan ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biomarkers; Catecholamines; DOPA; DOPAC; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; BIOLOGICAL MARKER; CATECHOL; FLUORODEOXYGLUCOSE F 18; DOPAMINE;

ADULT; AGED; ARTICLE; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DOPAMINE BLOOD LEVEL; DREAM; FAMILY HISTORY; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MIDDLE AGED; OLFACTORY NERVE DISEASE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THINKING; VISUAL HALLUCINATION; DISEASE EXACERBATION; FOLLOW UP; PRODROMAL SYMPTOM;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; AGED; BIOMARKERS; DISEASE PROGRESSION; DOPAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PRODROMAL SYMPTOMS;

EID: 85042200094     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2018.02.023     Document Type: Article

References (10)

1. Goldstein, D.S., Holmes, C., Bentho, O., Sato, T., Moak, J., Sharabi, Y., Imrich, R., Conant, S., Eldadah, B.A., Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Park. Relat. Disord. 14:8 (2008), 600–607.
2. Andersen, A.D., Blaabjerg, M., Binzer, M., Kamal, A., Thagesen, H., Kjaer, T.W., Stenager, E., Gramsbergen, J.B.P., Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. J. Neurochem. 141:4 (2017), 614–625.
3. Shi, M., Bradner, J., Hancock, A.M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., Jankovic, J., Zabetian, C.P., Kim, H.M., Leverenz, J.B., Montine, T.J., Ginghina, C., Kang, U.J., Cain, K.C., Wang, Y., Aasly, J., Goldstein, D., Zhang, J., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69:3 (2011), 570–580.
4. Ponsen, M.M., Stoffers, D., Booij, J., van Eck-Smit, B.L., Wolters, E., Berendse, H.W., Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56:2 (2004), 173–181.
5. Postuma, R.B., Gagnon, J.F., Bertrand, J.A., Genier Marchand, D., Montplaisir, J.Y., Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 84:11 (2015), 1104–1113.
6. Goldstein, D.S., Orthostatic hypotension as an early finding in Parkinson disease. Clin. Auton. Res. 16 (2006), 46–64.
7. Goldstein, D.S., Holmes, C., Sharabi, Y., Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 135:Pt 6 (2012), 1900–1913.
8. Nurmi, E., Ruottinen, H.M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., Rinne, J.O., Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov. Disord. 16:4 (2001), 608–615.
9. Jokinen, P., Helenius, H., Rauhala, E., Bruck, A., Eskola, O., Rinne, J.O., Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J. Nucl. Med. 50:6 (2009), 893–899.
10. Goldstein, D.S., Holmes, C., Lopez, G., Wu, Tianxia, Y. Sharabi, Cardiac sympathetic denervation predicts PD in at-risk individuals. Park. Relat. Disord., 2017 Oct 5, 10.1016/j.parkreldis.2017.10.003 pii: S1353-8020(17)30360-7, [Epub ahead of print].